Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Chengdu China (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2016
NCT03050177
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hunan Kelun Pharmaceutical Co., Ltd. | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (6)

Key: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (5) Acquired (1)

cetuximab (erbitux) (2 trials)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

skb264 (6 trials)

Drugs in Phase 2 Trials (7)

Key: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (5) Acquired (2)

a166 (2 trials)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

kl130008 (1 trial)

kl590586 (1 trial)

kl-a167 (4 trials)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (8)

anti-cd33 car-nk cells (1 trial)

bcma car-nk 92 cells (1 trial)

cll1-cd33 ccar t cells (1 trial)

cyclophosphamide (cytoxan) (3 trials)

fludarabine (fludara) (3 trials)

gefitinib (iressa) (2 trials)

kl340399 (2 trials)

skb315 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Colorectal Neoplasms (Phase 3)

Hodgkin Disease (Phase 2)

Lymphoma (Phase 2)

Malnutrition (Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 21